What Would Fundamental Change To Reimbursement Mean For Multinationals? – China Big Pharma Roundup
This article was originally published in PharmAsia News
Executive Summary
Although big pharma continued to show strong growth in China, the pace slowed in the first half of the fiscal year. While many stakeholders are focusing on the recent bribery scandal, perhaps a bigger worry is potential reimbursement reform, which could hurt multinationals where it matters most in China, off-patent products.
You may also be interested in...
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.